Single Intranasal Mucosal Mycobacterium bovis BCG Vaccination Confers Improved Protection Compared to Subcutaneous Vaccination against Pulmonary Tuberculosis

Infection and Immunity

Volumn 72, Issue 1, 2004, Pages 238-246

  Chen, Lihao ^a   Wang, Jun ^a   Zganiacz, Anna ^a   Xing, Zhou ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BCG VACCINATION; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNOSTIMULATION; LUNG LAVAGE; LUNG TUBERCULOSIS; LYMPH NODE; LYMPHOCYTE COUNT; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ANIMALS; BCG VACCINE; FEMALE; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NASAL MUCOSA; SPLEEN; TUBERCULOSIS, PULMONARY;

EID: 0348141905     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.72.1.238-246.2004     Document Type: Article

References (39)

1. Abolhassani, M., M. Lagranderie, P. Chavarot, A.-M. Balazuc, and G. Marchal. 2000. Mycobacterial bovis BCG induces similar immune responses and protection by rectal and parenteral immunization routes. Infect. Immun. 68:5657-5662.
2. Brewer, T. F. 2000. Preventing tuberculosis with BCG vaccine: a meta-analysis of the literature. Clin. Infect. Dis. 31(Suppl. 3):S64-S67.
3. Chambers, M. A., A. Williams, D. Gavier-Widen, A. Whelan, G. Hall, P. D. Marsh, B. R. Bloom, W. R. Jacob, and R. G. Hewinson. 2000. Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin. Infect. Immun. 68:7094-7099.
4. Colditz, G. A., T. F. Brewer, C. S. Berkey, M. E. Wilson, E. Burdick, H. V. Fineberg, and F. Mosteller. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698-702.
5. Davis, S. S. 2001. Nasal vaccines. Adv. Drug Deliv. Rev. 51:21-42.
6. Falero-Diaz, G., S. Challacombe, D. Banerjee, G. Douce, A. Boyd, and J. Ivanyi. 2000. Intranasal vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine 18:3223-3229.
7. Fine, P. E. 1995. Variation in protection by BCG: implication of and for heterologous immunity. Lancet 346:1339-1345.
8. Flynn, J. L., and J. Chan. 2001. Immunology of tuberculosis. Annu. Rev. Immunol. 19:93-129.
9. Gallichan, W. S., and K. L. Rosenthal. 1998. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J. Infect. Dis. 177:1155-1161.
10. Guleria, I., R. Teitelbaum, R. A. McAdam, G. Kalpana, W. R. Jacobs, Jr., and B. R. Bloom. 1996. Auxotrophic vaccines for tuberculosis. Nat. Med. 2:334-337.
11. Heritage, P. L., B. J. Underdown, A. L. Arsenault, D. P. Snider, and M. R. McDermott. 1997. Comparison of murine nasal-associated lymphoid tissue and Peyer's patches. Am. J. Respir. Crit. Care Med. 156:1256-1262.
12. Hoft, D. F., R. M. Brown, and R. B. Belshe. 2000. Mucosal BCG vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses. Clin. Infect. Dis. 30(Suppl. 3):S217-S222.
13. Isaka M, Y. Yasuda, S. Kozuka, T. Taniguchi, K. Matano, J. Maeyama, T. Komiya, K. Ohkuma, N. Goto, and K. Tochikubo. 1999. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. Vaccine 18:743-751.
14. Jackson, M., S. W. Phalen, M. Lagranderie, D. Ensergueix, P. Chavarot, G. Marchal, D. N. McMurray, B. Gicquel, and C. Guilhot. 1999. Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect. Immun. 67:2867-2873.
15. Kaufmann, S. H. E. 2000. Is the development of a new tuberculosis vaccine possible? Nat. Med. 6:955-960.
16. Kyd, J. M., A. R. Foxwell, and A. W. Cripps. 2001. Mucosal immunity in the lung and upper airway. Vaccine 19:2527-2533.
17. Lagranderie, M., P. Ravisse, G. Marchal, M. Gheorghiu, V. Balasubramanian, E. H. Weigeshaus, and D. W. Smith. 1993. BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route. Tuber. Lung Dis. 74:38-46.
18. Lagranderie, M., N. Winter, A. M. Balazuc, B. Gicquel, and M. Gheorghiu. 1998. A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. AIDS Res. Hum. Retroviruses 14:1625-1633.
19. Lagranderie, M., P. Chavarot, A. M. Balazuc, and G. Marchal. 2000. Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral and intragastric administration in mice. Vaccine 18:1186-1195.
20. Langermann, S., S. Palaszynski, A. Sadziene, C. K. Stover, and S. Koenig. 1994. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature 372:552-555.
21. Lefford M. J. 1977. Induction and expression of immunity after BCG immunization. Infect. Immun. 18:646-653.
22. Lyadova, I. V., H. M. Vordermeier, E. B. Eruslanov, S. V. Khaidukov, A. S. Apt, and R. G. Hewinson. 2001. Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-Y in their lungs. Clin. Exp. Immunol. 126:274-279.
23. Ogra, P. L., H. Faden, and R. C. Welliver. 2001. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14:430-445.
24. Orme, I. M., and F. M. Collins. 1986. Aerogenic vaccination of mice with M. bovis BCG. Tubercle 67:133-140.
25. Orme, I. M. 2001. The search for new vaccines against tuberculosis. J. Leukoc. Biol. 70:1-10.
26. Palendira, U., A. G. D. Bean, C. G. Feng, and W. J. Britton. 2002. Lymphocyte recruitment and protective efficacy against pulmonary mycobacterial infection are independent of the route of prior Mycobacterium bovis BCG immunization. Infect. Immun. 70:1410-1416.
27. Power, C. A., G. J. Wei, and P. A. Bretscher. 1998. Mycobacterial dose defines the Th1/Th2 nature of the immune response independent of whether immunization is administered by the intravenous, subcutaneous, or intradermal route. Infect. Immun. 66:5743-5750.
28. Schell, R. F., W. F. Ealey, G. E. Harding, and D. W. Smith. 1974. The influence of vaccination on the course of experimental airborne TB in mice. J. Reticuloendothel. Soc. 16:131-138.
29. Smith, D. A., T. Parish, N. G. Stoker, and G. J. Bancroft. 2001. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect. Immun. 69:1142-1150.
30. Stevceva, L., A. G. Abimiku, and G. Franchini. 2000. Targeting the mucosa: genetically engineered vaccines and mucosal immune responses. Genes Immun. 1:308-315.
31. Wakeham, J., J. Wang, J. Magram, K. Croitoru, R. Harkness, P. Dunn, A. Zganiacz, and Z. Xing. 1998. Lack of both types 1 and 2 cytokines, tissue inflammatory responses, and immune protection during pulmonary infection by Mycobacterium bovis BCG in IL-12-deficient mice. J. Immunol. 160:6101-6111.
32. Wakeham, J., J. Wang, and Z. Xing. 2000. Genetically determined disparate innate and adaptive cell-mediated immune responses to pulmonary Mycobacterium bovis BCG infection in C57BL/6 and BALB/c mice. Infect. Immun. 68:6946-6953.
33. Wang, J., K. Palmer, J. Lötvall, S. Milan, X.-F. Lei, K. I. Matthaei, J. Gauldie, M. Inman, M. Jordana, and Z. Xing. 1998. Circulating, but not local lung, IL-5, is required for the development of antigen-induced airway eosinophilia. J. Clin. Investig. 102:1132-1141.
34. Wang, J., J. Wakeham, R. Harkness, and Z, Xing. 1999. Macrophages area significant source of type 1 cytokines during mycobacterial infection. J. Clin. Investig. 103:1023-1029.
35. Wang, J., A. Zganiacz, and Z. Xing. 2002. Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation. Vaccine 20:2887-2898.
36. Wang J., and Z, Xing. 2002. Tuberculosis vaccines: the past, present and future. Expert Rev. Vaccines 1:341-354.
37. World Health Organization. 2001. Vaccine-preventable diseases-global summary (2001). World Health Organization, Geneva, Switzerland.
38. Xin, K. Q., T. Ooki, H. Mizukami, K. Hamajima, K. Okudela, K. Hashimoto, Y. Kojima, N. Jounai, Y. Kumamoto, S. Sasaki, D. Klinman, K. Ozawa, and K. Okuda. 2002. Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. Hum. Gene Ther. 13:1571-1581.
39. Xing, Z., A. Zganiacz, J. Wang, M. Divangahi, and F. Nawaz. 2000. IL-12-independent Th1-type immune responses to respiratory viral infection: requirement of IL-18 for IFN-γ release in the lung but not for the differentiation of viral-reactive Th1-type lymphocytes. J. Immunol. 164:2575-2584.